{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "JBIO",
  "name": "Jade Biosciences, Inc.",
  "url": "https://orbyd.app/dossiers/JBIO/",
  "json_url": "https://orbyd.app/dossiers/JBIO.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put a rival on-market years before JADE101's ~2029 launch. The $172.5M raise at $15 is fully placed; next own readout is 2027. Re-base holds near $21 — constructive but catalyst-less, so no momentum leg to buy yet.",
  "invalidation_trigger": "A daily close below $18 forfeits the offering-absorption shelf and points the new float toward the $15 placement floor; compounded if TRUTAKNA's Q3 2026 confirmatory eGFR compresses the APRIL/BAFF category multiple while JBIO has no catalyst before the 2027 JUNIPER interim.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Both binaries SPENT: JADE101 Phase 1 interim (2026-06-01, ~70% IgA reduction at 700mg to 12 weeks, 24.2-day half-life, >90% free-APRIL suppression, q12w dosing, no SAEs) + Vera TRUTAKNA (atacicept) FDA accelerated approval (2026-07-07). No JADE101-specific catalyst until 2027.",
    "June follow-on FULLY PLACED: 11.5M sh @ $15.00 = $172.5M gross incl. full over-allotment (base 10.0M + 1.5M greenshoe), ~$161M net. NOT a second raise — the July-15 '$172.5M closing' headline is the greenshoe-inclusive final of the June deal. Float ~49.3M → ~60.8M (~23%). $15.00 = underwritten reference floor. Runway into 1H 2028.",
    "DORMANT: no momentum leg between now and 2027 catalysts (JUNIPER Phase 2 interim, JADE201 FIH, Phase 3 start H1 2027). Stand aside until a fresh catalyst or a clean re-base. Re-acceleration = daily reclaim of ~$23-24 on >=2x ADV with a dated catalyst.",
    "Binary clinical biotech — sizing cap 1-2% per name, hard stop, NEVER average down. Biomarker!= clinical efficacy; the equity re-rating proof is Phase 2 proteinuria/eGFR in 2027.",
    "Competitive backdrop: TRUTAKNA now on-market (once-weekly SC, dual BAFF/APRIL) + sparsentan (TVTX) already approved vs JADE101 ~2029 launch = 2-3yr first-mover disadvantage; JADE101's edge is q12w quarterly dosing IF it reaches market.",
    "Category swing factor to watch: TRUTAKNA confirmatory eGFR data expected Q3 2026 — a miss pressures the whole APRIL/BAFF lane including JBIO.",
    "Earnings ~2026-08-13 (est.) — Q2 corporate update, non-binary. Enter blackout ~2026-08-08; avoid new entries inside blackout.",
    "Sell-side: 10 analysts Strong Buy, avg PT ~$48.50 (high $74, low $40), UBS Buy $45 (2026-06-15). Do NOT buy a catalyst-less biotech on analyst-target FOMO — 12+ month catalyst gap = dead-money risk."
  ],
  "body_markdown": "## Current Thesis\nJade is a clinical-stage IgA-nephropathy (IgAN) biotech whose two near-term binaries have both printed, and both are now spent. JADE101's Phase 1 interim (2026-06-01) delivered a best-in-class biomarker read: ~70% mean IgA reduction at 700 mg sustained to 12 weeks, a 24.2-day half-life with >90% free-APRIL suppression, quarterly (q12w) maintenance dosing supported by simulation, and no SAEs or discontinuations. The category read-through then landed on 2026-07-07, when Vera's atacicept won FDA accelerated approval as TRUTAKNA for primary IgAN — validation of the APRIL/BAFF mechanism, but also confirmation that a dual BAFF/APRIL agent (once-weekly SC) is on-market now, alongside already-approved Travere sparsentan, versus JADE101's ~2029 launch. The June follow-on closed fully greenshoed at 11.5M shares / $172.5M gross ($15.00), extending runway into 1H 2028. With the June data and the July competitor approval both behind it, there is no JADE101-specific catalyst until 2027 (JUNIPER Phase 2 interim, JADE201 first-in-human, Phase 3 start). The stock has held a constructive re-base near $21, above the ~$18 absorption shelf and well above the $15 placement floor, and the sell-side sits far higher (avg PT ~$48.50, high $74). For a narrative-momentum approach, strength without a driver does not constitute a setup; this reads as dead-money drift until a fresh readout re-accelerates the story or a clean, volume-backed base offers an entry.\n\n## Bull Case\n- **Phase 1 cleared the bar (2026-06-01)**: ~70% mean IgA reduction at 700 mg to 12 weeks; 24.2-day half-life; >90% free-APRIL suppression; single SC doses to 1,400 mg tolerated. Tops first-generation anti-APRIL and dual APRIL/BAFF agents on potency and durability.\n- **Regulator de-risked the mechanism**: TRUTAKNA's 2026-07-07 accelerated approval confirms FDA will accept proteinuria reduction as a surrogate endpoint in IgAN, clarifying the registrational path JADE101's Phase 3 will travel.\n- **Quarterly dosing is the commercial differentiator**: q12w SC maintenance (350 mg after 700 mg induction, per simulation) undercuts once-weekly TRUTAKNA and other more-frequent regimens on convenience, if the biomarker translates to clinical benefit.\n- **Clean safety read**: no SAEs, no discontinuations, no hypogammaglobulinemia; AEs limited to headache, URTI, injection-site erythema, pyrexia. Removes the LFT/cytopenia tail that overhung the pre-data setup.\n- **Capital fully in hand**: June follow-on closed at 11.5M shares / $172.5M gross including full over-allotment (~$161M net), on top of $336.2M cash (2025-12-31). Runway into 1H 2028 with no forced raise into Phase 2 data.\n- **Sell-side clustered far above spot**: 10 analysts at Strong Buy consensus, avg PT ~$48.50 (high $74, low $40); UBS Buy $45 initiation (2026-06-15). Every published target sits roughly 2x the current quote.\n- **Pipeline breadth building**: JADE201 (afucosylated anti-BAFF-R) and undisclosed JADE301 add optionality beyond the lead asset.\n\n## Bear Case\n- **No own catalyst until 2027**: the events the equity was coiled around have passed. JUNIPER Phase 2 interim, JADE201 FIH, and Phase 3 start are all 2027; nothing JADE101-specific moves the tape in between.\n- **The competitor is now on-market**: TRUTAKNA's accelerated approval (2026-07-07) plus already-approved sparsentan means JADE101 would launch (~2029) into an established field — a 2-3 year first-mover disadvantage the story must overcome largely on dosing convenience.\n- **Biomarker is not clinical efficacy**: ~70% IgA reduction is a pharmacodynamic marker in healthy volunteers, not proteinuria/eGFR benefit in patients. The equity re-rating proof is Phase 2 clinical data in 2027, and the Phase 1 read carries translation risk.\n- **Dilution is real and repriced low**: 11.5M new shares at $15.00 (~23% of the pre-deal float), with $15 the hard underwritten reference. Placement holders sit ~40% in the money near $21 — latent supply overhang if momentum fades.\n- **Accelerated-approval fine print cuts both ways**: TRUTAKNA's continued approval hinges on confirmatory eGFR data (expected Q3 2026); a wobble there would pressure the entire APRIL/BAFF category, JADE101 included.\n- **Catalyst-gap tape**: a post-binary, pre-revenue biotech with no readout for 12+ months tends to bleed on low volume regardless of price targets.\n\n## Setup & Price Structure\n- Last ~$21 (2026-07-12 ~$20.95; 2026-07-07 intraday $21.17–$22.70). 52-week range ~$6.6–$28.\n- Re-base intact: ~$16.50 post-deal low (early June) → low-$20s, reclaiming the ~$18 offering-absorption shelf; the $15.00 underwritten reference sits beneath as a harder floor.\n- Mid-range, not stretched: trades roughly mid its 52-week band and is not extended above moving averages — no mean-reversion short signal, but no breakout thrust either.\n- Volume has normalized post-catalyst — a consolidation rather than a trend; no distribution spike and no accumulation thrust.\n- A clean momentum entry needs a daily reclaim of prior-range highs (~$23–24) on ≥2x average volume, ideally against a fresh dated catalyst. Absent that, structure is constructive but inert.\n\n## Catalyst Calendar (next 30 days)\n\n- **No JADE101-specific value catalyst in the window.** Next company-dated readouts are 2027: JUNIPER Phase 2 interim and JADE201 first-in-human interim, with registrational Phase 3 guided H1 2027.\n- **~2026-08-13 (est.)**: Q2 2026 results / corporate update — a cash-runway and pipeline-progress print, not a binary readout; earnings blackout begins ~2026-08-08.\n- No FDA/PDUFA dates and no clustered analyst actions pending for JADE101 in the next 30 days.\n\n## Elapsed catalysts\n\n- **2026-07-07 (elapsed)**: Vera TRUTAKNA accelerated approval — category read-through already realized. The live category input now is TRUTAKNA's confirmatory eGFR data expected Q3 2026, plus early competitor launch commentary. *(passed 33d ago)*\n\n## What Would Change Our Mind\n- **Re-acceleration (constructive)**: a daily close reclaiming the prior-range high near $23–24 on ≥2x average volume, the new float visibly absorbed, and a dated catalyst pulled forward — that converts the inert re-base into a tradable momentum leg.\n- **Thesis break (destructive)**: a daily close below $18 forfeits the absorption shelf and points the new float toward the $15 placement floor; risk compounds if TRUTAKNA's Q3 2026 confirmatory eGFR disappoints and compresses the APRIL/BAFF category multiple while JADE101 has no offsetting catalyst before 2027.\n- A JUNIPER/JADE201 timeline pull-forward, a partnership, or an unsolicited bid would re-open the narrative early; the absence of any of these keeps the name dormant.\n\n## Correlation Notes\n- Tightest read-through is the IgAN / APRIL-BAFF complex: Vera (VERA, atacicept/TRUTAKNA), Travere (TVTX, sparsentan), Novartis (Fabhalta / atrasentan via ex-Chinook), and other nephrology-immunology names. Between its own catalysts, JADE101 trades as a sympathy beta to category data and approvals rather than on independent flow.\n- TRUTAKNA's confirmatory eGFR (Q3 2026) is the shared category swing factor — a positive read lifts the whole APRIL/BAFF lane; a miss pressures it, JBIO included.\n- Broader driver is small-cap clinical-biotech risk appetite (XBI/IBB, the rate path). As a pre-revenue, cash-heavy, catalyst-gap name, JBIO is highly beta to biotech risk-on/off and to any single-name financing or dilution headlines across the group.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-07-18T07:54:38+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}